BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 226 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q1 2021. The put-call ratio across all filers is 1.62 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $4,327,000 | -63.4% | 36,491 | -57.5% | 0.55% | -55.8% |
| Q4 2021 | $11,838,000 | -2.3% | 85,902 | -1.5% | 1.25% | -0.6% |
| Q3 2021 | $12,115,000 | +9.5% | 87,213 | -23.4% | 1.26% | +13.3% |
| Q2 2021 | $11,059,000 | -0.7% | 113,918 | -30.1% | 1.11% | +5.0% |
| Q1 2021 | $11,137,000 | +95.1% | 162,934 | +144.6% | 1.06% | +74.8% |
| Q4 2020 | $5,709,000 | +36.2% | 66,612 | +3.3% | 0.60% | -1.3% |
| Q3 2020 | $4,193,000 | -12.2% | 64,495 | -1.2% | 0.61% | -19.9% |
| Q2 2020 | $4,775,000 | +37.5% | 65,308 | -36.0% | 0.76% | -0.5% |
| Q1 2020 | $3,472,000 | -4.7% | 102,034 | +52.5% | 0.77% | +29.1% |
| Q4 2019 | $3,642,000 | -19.9% | 66,899 | -38.6% | 0.60% | -22.7% |
| Q3 2019 | $4,544,000 | -8.6% | 108,925 | -4.1% | 0.77% | +0.1% |
| Q2 2019 | $4,973,000 | +40.4% | 113,575 | +65.1% | 0.77% | +40.1% |
| Q1 2019 | $3,541,000 | – | 68,789 | – | 0.55% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 2,111,111 | $144,294,000 | 54.16% |
| Knoll Capital Management, LLC | 856,844 | $58,565,000 | 38.16% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,123,271 | $145,126,000 | 21.73% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 860,261 | $58,799,000 | 6.01% |
| ARS Investment Partners, LLC | 561,442 | $38,375,000 | 4.46% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $12,057,000 | 3.19% |
| Eventide Asset Management | 2,015,000 | $137,725,000 | 2.04% |
| Avidity Partners Management LP | 1,049,800 | $71,754,000 | 1.98% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,089 | $3,424,000 | 1.87% |
| Nicholas Investment Partners, LP | 375,654 | $25,676,000 | 1.79% |